Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
24.7M
-
Shares change
-
+3.63M
-
Total reported value, excl. options
-
$551M
-
Value change
-
+$80.3M
-
Put/Call ratio
-
0.84
-
Number of buys
-
48
-
Number of sells
-
-42
-
Price
-
$22.30
Significant Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q2 2018
141 filings reported holding AXDX - Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share as of Q2 2018.
Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.7M shares
of 27.8M outstanding shares and own 88.96% of the company stock.
Largest 10 shareholders include ORACLE INVESTMENT MANAGEMENT INC (4.27M shares), CREDIT SUISSE AG/ (3.48M shares), Birchview Capital, LP (2.18M shares), BlackRock Inc. (1.75M shares), VANGUARD GROUP INC (1.28M shares), CANNELL PETER B & CO INC (1.12M shares), ArrowMark Colorado Holdings LLC (689K shares), BLAIR WILLIAM & CO/IL (645K shares), NEXT CENTURY GROWTH INVESTORS LLC (612K shares), and Nuveen Asset Management, LLC (553K shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.